Triple vasodilator therapy in pulmonary arterial hypertension associated with congenital heart disease.

Raquel Luna López Teresa Segura de la CalFernando Sarnago CebadaIrene Martin de MiguelWilliams HinojosaAlejandro Cruz-UtrillaMaria Teresa VelazquezJuan F DelgadoAlberto MendozaFernando Arribas YnsaurriagaPilar Escribano-Subías

Published in: Heart (British Cardiac Society) (2023)

Triple therapy with prostanoids is safe and effective for patients with PAH-CHD, improving FC, 6MWTD and NT-proBNP levels over 2 years. The treatment is particularly beneficial for patients with pre-tricuspid defects and non-Eisenmenger PAH-CHD.

Keyphrases

pulmonary arterial hypertension
pulmonary artery
pulmonary hypertension
mitral valve
heart failure
stem cells
mesenchymal stem cells
coronary artery
bone marrow
left ventricular
cell therapy
replacement therapy
chemotherapy induced